In order to clarify the mechanism of hypertension induced by a nitric oxide (NO) synthase inhibitor, L-NG-nitro-L-arginine (LNNA), metabolites of NO, catecholamines, and hemodynamic parameters were measured during 7 days of oral administration of LNNA in rats. Control rats received either L-arginine (L-Arg) or the vehicle. Systolic blood pressure, measured by the tail-cuff method was elevated throughout the period of LNNA administration, but that in the two control groups was not influenced by treatment. Heart rate decreased on the second day only in LNNA-treated rats. Although L-Arg treatment had no influence, LNNA markedly decreased the plasma level and the urinary excretion of nitrate ions (NO3-). Urinary excretion of noradrenaline was significantly decreased on the second day of LNNA administration and returned to the control level thereafter. When hemodynamic changes were measured by using radioactive microspheres, LNNA was found to increase blood pressure by markedly increasing total peripheral resistance. Cardiac output was decreased by LNNA. L-Arg, again, did not influence the hemodynamic variables as compared with the vehicle control group. The regional vascular resistance index was increased by LNNA in many tissues and organs, except the brain and the heart. Regional blood flow, on the other hand, was significantly decreased only in the liver and skin by LNNA. The marked reduction in NO3-in urine by LNNA-treatments may indicate that the measured NO3-is exclusively of endogenous origin, and that inhibition of NO production causes elevation of blood pressure by constricting peripheral -arteries. Sympatholytic responses by the baroreceptor reflex were thereby evident only on the second and the third days, which was indicated by bradycardia and suppression of noradrenaline excretion into urine. These results indicate that the inhibition of NO synthase actually decreases production of endogenous NO, and that the hypertension caused by decreases in NO production is due to elevation of total peripheral vascular resistance. (Hypertens Res 1995; 18: 319-324) 
Mechanism
In order to clarify the mechanism of hypertension induced by a nitric oxide (NO) synthase inhibitor, L-NG-nitro-L-arginine (LNNA), metabolites of NO, catecholamines, and hemodynamic parameters were measured during 7 days of oral administration of LNNA in rats. Control rats received either L-arginine (L-Arg) or the vehicle. Systolic blood pressure, measured by the tail-cuff method was elevated throughout the period of LNNA administration, but that in the two control groups was not influenced by treatment. Heart rate decreased on the second day only in LNNA-treated rats. Although L-Arg treatment had no influence, LNNA markedly decreased the plasma level and the urinary excretion of nitrate ions (NO3-). Urinary excretion of noradrenaline was significantly decreased on the second day of LNNA administration and returned to the control level thereafter. When hemodynamic changes were measured by using radioactive microspheres, LNNA was found to increase blood pressure by markedly increasing total peripheral resistance. Cardiac output was decreased by LNNA. L-Arg, again, did not influence the hemodynamic variables as compared with the vehicle control group. The regional vascular resistance index was increased by LNNA in many tissues and organs, except the brain and the heart. Regional blood flow, on the other hand, was significantly decreased only in the liver and skin by LNNA. The marked reduction in NO3-in urine by LNNA-treatments may indicate that the measured NO3-is exclusively of endogenous origin, and that inhibition of NO production causes elevation of blood pressure by constricting peripheral -arteries. Sympatholytic responses by the baroreceptor reflex were thereby evident only on the second and the third days, which was indicated by bradycardia and suppression of noradrenaline excretion into urine. These results indicate that the inhibition of NO synthase actually decreases production of endogenous NO, and that the hypertension caused by decreases in NO production is due to elevation of total peripheral vascular resistance. (Hypertens Res 1995; 18: 319-324)
Key Words: nitric oxide, nitric oxide synthase inhibitor, hypertension, nitrate ion, catecholamine, hemodynamics A potent vasorelaxing factor of endothelium origin (EDRF) is thought to be endogenous nitric oxide ( NO), produced enzymatically from L-arginine by a NO synthase (1-4). L-NG-monomethyl L-arginine (LMMA) and L-NG-nitro-L-arginine (LNNA) inhibit the NO synthase, and are believed to reduce the production of endogenous NO (1). NO is unstable and supposed to be degraded into nitrite (N02-) and nitrate (N03-) ions (5, 6). In fact, relatively large amounts of N03-exist in plasma and urine. Therefore, it may be reasonable to measure N02 and N03-as indices of endogenous NO production. However, there are many probable sources of N03-besides endothelial NO, such as that in diet, inspired air (7), drinking water, leukocytes (8) and autonomic nerve endings (9). The source of N02 and N03-in biological fluids has not been clarified. 
Materials and Methods
Eight-week-old male Wistar rats (n = 40) They were divided into three groups, were used. and each group (8 rats) received either distilled water, L-Arg (1 mg/ml) dissolved in distilled water or, LNNA (1 mg/ml) dissolved in distilled water as drinking water. They were allowed free access to the drug-solution or the vehicle and a normal rat chow (Oriental East Co. Ltd., Tokyo). They were normally housed 4 rats per cage, with the light cycle of 12 hours of day and night. When metabolic studies were conducted, each rat was housed separately in a metabolic cage for 24 hours with the same drinking water and diets, and with the same day-night light cycle. Urine was collected in a container with 5 ml of 1 N HCl on the 2nd, 4th, 5th and the 6th days after the start of the treatment. Systolic blood pressure was measured by the tail-cuff method (Muromachi Kikai Co. Ltd., Tokyo) on the 3rd and 6th days. The serum N03-levels were measured on the 7th day immediately after the measurement of hemodynamic variables. Using other two groups of rats treated with LNNA (n = 8) or the vehicle (n = 8), serum levels of N03-were measured on the 3rd day under anesthesia with urethane to confirm the results on the 7th day of treatment.
Measurement o f N03 Serum and urine samples were frozen at -40°C until NO3-was measured. The concentration of N03-(saM) was determined by high-performance liquid chromatography (HPLC) using an anion exchange column (IC-Pak A, Waters, Milford, MA). The sample, 10 it of serum or 3 p1 of urine, was deproteinized by passing through a hydroxyapatite column (Pentax, Asahi Optical Co., Ltd., Tokyo), and the non-protein fraction was trapped on a concanavalin A column (IC-Conc A, Tosoh Co., Osaka). Then, the trapped fraction was released by the elution buffer (phosphate buffer, 0.02 mM, pH 8.0, 1.2 ml/min), which was analyzed with a IC-Pak A column. The hydroxyapatite column was washed with 4 M phosphate buffer by switching the bulb while the sample was being analyzed with the anion column, in order to prepare for the next sample. The entire system was connected and integrated to form an automatic system by the combining HPLC components (LC-6A and 7A, Shimadzu Co. Ltd., Kyoto). Each sample was measured automatically every 28 min. The amount of urinary excretion of N03-(mmol/d) was calculated by multiplying the urinary concentration of N03-by the 24-h urinary volume. The intra-and inter-assay coefficients of variation were 2.1 and 3.5% in pooled rat serum, and 1.8 and 3.1% in pooled rat urine, respectively.
Assay for Catecholamines Catecholamines in urine samples were extracted with activated aluminum oxide (Alumina, activated, Wako Pure Chemical Industries Ltd., Osaka, Japan). Adrenaline and noradrenaline were assayed by a HPLC (HLC 10A, Shimadzu, Kyoto) system with electrochemical detection (Coulochem II, ESA Inc., Bedford, MA). The recovery ratio of plasma samples was 68.0 ± 2.03% for noradrenaline and 61.7 ± 3.58% for adrenaline. Coefficients of variation for noradrenaline and adrenaline were 3.99%, and 6.92%, respectively.
Measurement o f Hemodynamics
All experiments were performed under anesthesia with urethane (1.1 g/kg, i.p.). Catheters were inserted into the femoral artery and vein, and into the left cardiac ventricle through the right carotid artery. Blood pressure was recorded continuously during the experiments by connecting the femoral arterial catheter to a small volume displacement transducer (TP-200T, Nihon Kohden, Tokyo), and pulse rate triggered by the phasic arterial pulse was calculated automatically with a tachometer (SEN-6104, Nihon Kohden, Tokyo). After recording blood pressure and heart rate for more than 10 min until the stabilization of these variables, radioactive microspheres (15 am in diameter, labeled with 57Co and suspended in normal saline plus 0.019 o Tween 80, NEM-022A, New England Nuclear) were injected into the left ventricle, and a reference sample, 0.45 ml, was collected for 30 seconds from the femoral artery. The methods are described in detail elsewhere (10). Cardiac output measured by an electromagnetic flow meter well correlated with the results of this radioactive microsphere method (r = 0.86, n=12, p<0.001).
Study Drugs and Statistical Analysis L-Arg (Sigma Chemicals, St. Louis, MO) and LNGnitro-L-arginine (Aldrich Chemicals, Milwaukee, WI) were used. Data, expressed as mean ± SEM, from three groups of rats were compared by analysis of variance; for F ratios significant at 5 % or less, differences between pairs of means were examined by Duncan's new multiple range test. Data from only two groups were compared by using Student's t-test.
Results Blood Pressure and Pulse Rate Systolic blood pressure (SBP) on both the 3rd and 6th days was significantly elevated in LNNA-treated rats, as compared with the L-Arg group and the vehicle group (Fig. 1) . Blood pressure was not influenced by L-Arg treatment. Pulse rate was significantly decreased on the 3rd day of the LNNA treatment, and returned to the control level on the 6th day. It was not influenced in groups receiving LArg or the vehicle. These effects were not related to changes in body weight because there was no difference between any groups.
Urine Volume Urinary Excretions o f Nitrate Ions (N03) Urine volume was comparable in the three groups of rats on all four days of measurement.
The concentration of N02-in urine was extremely low, and the level was under the detection limit of the HPLC system (Fig. 2) . Since it is thought that N02-is converted exclusively into N03-, in this study, we measured only the concentration of N03-. As shown in Fig. 2 , urinary N03-levels were markedly lower in the LNNA group than in the water group and L-Arg group throughout the study period.
Serum Levels o f N03 Serum N03-concentrations were measured on the 3rd and the 7th days in different groups of rats (Fig.  3) . On the third day, serum N03-concentrations were measured only in two groups. Serum N03 concentration was markedly lower (about 1l3 that of control) in the LNNA group than in the vehicle control group. On the 7th day, a similar reduction was seen in the LNNA group. Although the mean serum N03-concentration was slightly higher in the L-Arg group than in the vehicle group, the difference was not significant.
Urinary Catecholamines
All three measured catecholamines tended to be increased in rats treated with L-Arg, but statistical significance was not reached (Fig. 4 ). The noradrenaline level in the LNNA group on the 2nd day of the treatment was significantly lower than those in the other two groups.
Hemodynamic Alterations Caused by Chronic Inhibition of Nitric Oxide Production Mean arterial pressure (MAP), measured directly through the femoral catheter, was significantly elevated in anesthetized rats treated with LNNA, but was not influenced by L-Arg (Fig. 5, 6 ). Heart rate was not influenced by either LNNA or L-Arg. On the other hand, cardiac output was significantly decreased by treatment with LNNA. Therefore, the calculated total vascular resistance index was markedly increased in rats treated with LNNA.
The regional arterial resistance index significantly increased in many organs and tissues, except the of of brain and the heart. On the other hand, regional blood flow was well preserved, even after arterial vasoconstriction because the perfusion pressure was markedly elevated. A significant decrease in blood flow occurred only in the liver and skin. Discussion NO binds to hemoglobin (Hb) in erythrocytes to form NOHb where it is immediately converted to N02-, and finally to N03-(5, 6). NO is exclusively excreted into the urine in the form of N03-. Therefore, the N03-measured in serum and urine in the present study may have been derived from a number of sources, such as food, drinking water, inspired air, Kupffer cells, macrophages, neutrophils, autonomic nerve terminals, and endothelial cells. However, because the amount of N03-excreted into the urine was markedly reduced by a NO synthase inhibitor in this study, the measured N03 was apparently derived exclusively from endogenously formed NO. Furthermore, since endothelium is in direct contact with the blood stream and has an enormous surface area, the major part of circulating and urinary N03-is likely to be of endothelial cell origin. Assuming this is true, this would be the first report to show by measuring N03-in biological fluid that a NO synthase inhibitor decreases NO formation in vivo.
Suppression of N03-levels in serum was smaller than that in urine. The amount of LNNA given to rats, estimated on the basis of the urine volume, was approximately 10 mg/d. Since inhibition of NO synthase activity by this amount of LNNA was most likely incomplete, small amounts of NO may have been continuously produced. Because the molecular weight of NO3-is very small and this ion is excreted rapidly into urine, serum levels are expected to be consistently low. Therefore, even if the pro- duction of N03-is drastically changed, the change in the serum level might be very small. The urinary excretion of N03-is therefore superior to the serum level as an index of endogenous production of NO.
The hypertension produced by chronic administration of LNNA was associated with sympathetic inhibition during the early part of treatment, as shown by the decrease in urinary noradrenaline excretion and the occurrence of bradycardia. This early effect is most likely caused by the baroreceptor reflex due to vasopressor responses of peripheral origin. This is supported by hemodynamic changes, which indicated that LNNA produced systemic arterial vasoconstriction in all but a few organs. Further support is provided by a study in humans by Hansen et al. (11) , in which LMMA, injected intravenously, increased blood pressure and suppressed sympathetic activity. However, this sympathetic inhibition was seen only in the first few days of treatment in the present study, and sympathetic activity returned to the control level subsequently. This may mean that the baroreceptor threshold was reset to a higher level of blood pressure. Since it has been reported that a NO synthase exists in the central nervous system (12, 13) , and that the inhibition of NO synthase in brain elevates blood pressure (14) , LNNA might have affected brain NO synthase and increased sympathetic outflow to a level similar to that in the control rats. Although the exact mechanism of this baroreceptor resetting is unknown, this may play a major part in maintaining elevated blood pressure during NO synthase inhibition.
The main cause of LNNA-induced hypertension is obviously vasoconstriction. Hemodynamic studies by radioactive microsphere technique clearly indicated that the systemic arterial beds are constricted by NO synthase inhibition. All tissues and organs except the brain and several other organs were affected by NO synthase inhibition. This clearly contrasts with the vascular effects of vasopressor peptides such as angiotensin II (15) and endothelin (16) , which predominantly cause constriction of splanchnic vascular beds. Because cardiac output was decreased by LNNA, the vasopressor response is due solely to the increased vascular resistance. Similar results have been reported by Bank et al. (17) . The decreased cardiac output is due to increased afterload on the heart. Vascular beds in the brain and the heart were beyond the range of effects of NO synthase inhibition. Since a NO donor, nitroglycerin, dilates coronary arteries, it is used for the treatment of angina pectoris. One of the adverse effects of nitroglycerin is headache due to vasodilation of the cerebral arteries. Therefore, vascular beds in the heart and the brain are apparently sensitive to NO, but NO synthase inhibition had no effect on these organs in this experiment. Since it is known that the heart (18) and the brain can produce NO, a compensatory, vasodilator mechanism may occur in response to the vasoconstriction caused by NO synthase inhibition.
LNNA was found to elevate blood pressure by decreasing the production of NO and by constricting peripheral arteries. The decreased cardiac output and the increased total peripheral resistance evoked by LNNA resembles the hemodynamic pattern seen in patients with established hypertension (19) . Therefore, endothelial functions to produce NO may be deficient in patients with established hypertension. 
